Medical Oncology Clinical Trial
Official title:
An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers
Verified date | July 2020 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Characterize the safety, tolerability, ECG effects, pharmacokinetics and immunogenicity of anetumab ravtansine given as single agent and after inhibition of CYP3A4 and P-gp by concomitant administration of itraconazole in subjects with mesothelin-expressing advanced solid cancers
Status | Completed |
Enrollment | 63 |
Est. completion date | August 5, 2019 |
Est. primary completion date | June 27, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects must have histologically confirmed, locally advanced or metastatic solid cancers of the following histological types: 1. predominantly epithelial (=50% tumor component) pleural or peritoneal mesothelioma 2. epithelial ovarian cancer (fallopian tube and primary peritoneal cancers are eligible) 3. adenocarcinoma of the pancreas, 4. triple-negative adenocarcinoma of the breast 5. non-small-cell adenocarcinoma of the lung 6. gastric cancer (including gastro-esophageal junction) 7. colon cancer 8. cholangiocarcinoma 9. Thymic carcinoma - Subjects must have no standard therapy available, or have actively refused standard therapy - Subjects must provide samples of archival tumor tissue collected and submitted anytime during the study - Subjects must have a life expectancy of at least 12 weeks - Subjects must have ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 - Subjects must have adequate bone marrow, renal and hepatic function and coagulation - Subjects must have normal or clinically insignificant ECG at screening - Women of reproductive potential must have a negative serum pregnancy test obtained within 3 days before the start of anetumab ravtansine - Women of childbearing potential and fertile men must agree to use adequate contraception when sexually active. This applies from the time period between signing of the informed consent until at least 6 months after the last administration of the last study drug. Male patients with a female partner of childbearing potential must use a condom and ensure that an additional form of contraception is also used during treatment and until 6 months after last study drug administration. Exclusion Criteria: - Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated = 3 years before the start of anetumab ravtansine - New or progressive brain or meningeal or spinal metastases - Corneal epitheliopathy or any eye disorder that may predispose the subjects to drug-induced corneal epitheliopathy, or may interfere with diagnosis of treatment-emergent corneal epitheliopathy at the ophthalmologist's or the investigator's discretion - History or current evidence of - biliary cirrhosis - malignant biliary obstruction unless the bile flow to the gastrointestinal tract is maintained by a fully operational biliary stent - CTCAE (Common Terminology Criteria for Adverse Events) Grade =2 bleeding disorder within 4 weeks before the start of anetumab ravtansine - uncontrolled cardiovascular disease or uncontrolled hypertension - Long QT Syndrome - HIV infection - Hepatitis B or C infection - Had a major surgery or significant trauma within 4 weeks before the start of anetumab ravtansine - Had solid organ or bone marrow transplantation - Have LVEF (left ventricular ejection fraction) <50% at screening - Have QTc >450 ms or heart rate =100 bpm or =45 bpm at screening - Poor CYP2D6 metabolizers based on the screening test for genetic polymorphisms in CYP2D6 metabolizing capacity |
Country | Name | City | State |
---|---|---|---|
Australia | Blacktown Cancer & Haematology Centre | Blacktown | New South Wales |
Australia | Epworth HealthCare | Richmond | Victoria |
Belgium | CU Saint-Luc/UZ St-Luc | Bruxelles - Brussel | |
Belgium | UZ Gent | Gent | |
France | Hôpital Henri Mondor | Creteil | |
France | Centre Georges Francois Leclerc Dijon | Dijon | |
France | Hôpital de la Timone - Marseille | Marseille | |
Netherlands | Nederlands Kanker Instituut | Amsterdam | |
Netherlands | VUmc | Amsterdam | |
Netherlands | Universitair Medisch Centrum St. Radboud | Nijmegen | |
Spain | Ciutat Sanitària i Universitaria de la Vall d'Hebron | Barcelona | |
Spain | Fundacion Jimenez Diaz (Clinica de la Concepcion) | Madrid | |
Spain | Hospital Virgen de la Victoria | Málaga | |
United States | University Hospitals Cleveland Medical Center | Cleveland | Ohio |
United States | Mary Crowley Medical Research Center | Dallas | Texas |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | UCLA-Santa Monica Medical Center | Santa Monica | California |
Lead Sponsor | Collaborator |
---|---|
Bayer |
United States, Australia, Belgium, France, Netherlands, Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PR interval duration | ECG evaluation | Up to 2 months per patient | |
Primary | QRS interval duration | ECG evaluation | Up to 2 months per patient | |
Primary | QT interval duration | ECG evaluation | Up to 2 months per patient | |
Primary | Abnormal T/U waves | ECG evaluation | Up to 2 months per patient | |
Primary | Heart rate | ECG evaluation | Up to 2 months per patient | |
Primary | Cycle 1+2 AUC (area under the plasma concentration vs. time curve from zero to infinity after single (first) dose) of BAY94-9343 analytes | At pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 5h, 8h, 10h, 24h, 48h, 168h, 336h, 480h and 504h after each dose during first 42 days of the study | ||
Primary | Cycle 1+2 AUC(0-tlast) (AUC from time zero to the last data point > LLOQ [lower limit of quantification]) of BAY94-9343 analytes | At pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 5h, 8h, 10h, 24h, 48h, 168h, 336h, 480h and 504h after each dose during first 42 days of the study | ||
Primary | Cycle 1+2 Cmax (maximum drug concentration in plasma after the first dose administration) of BAY94-9343 analytes | At pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 5h, 8h, 10h, 24h, 48h, 168h, 336h, 480h and 504h after each dose during first 42 days of the study | ||
Primary | QTcF (QT interval, corrected for heart rate according to Fridericia's formula) interval duration | ECG evaluation | Up to 2 months per patient | |
Primary | QTcP (QT interval, corrected for heart rate using a population-specific correction) interval duration | ECG evaluation | Up to 2 months per patient | |
Secondary | Incidence of serious adverse events | Up to 6 months per patient | ||
Secondary | Incidence of non-serious adverse events | Up to 6 months per patient | ||
Secondary | Incidence of positive anti-drug antibody titer | Up to 6 months per patient | ||
Secondary | Incidence of neutralizing antibody titers | Up to 6 months per patient | ||
Secondary | Cycle 3 Cmax,md (Cmax after multiple-dose administration) of BAY94-9343 analytes | At pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 5h, 8h, 168h, 336h and 504h between 43rd and 64th days of the study | ||
Secondary | Cycle 3 AUC(0-tlast)md (AUC(0-tlast) after multiple-dose administration) of BAY94-9343 analytes | At pre-dose, 0.5h, 1h, 1.5h, 2h, 3h, 5h, 8h, 168h, 336h and 504h between 43rd and 64th days of the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02253420 -
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
|
Phase 1 | |
Completed |
NCT02357953 -
Transpulmonary Thermodilution Using an Implented Central Venous Access Port
|
N/A | |
Completed |
NCT02645357 -
Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients
|
N/A | |
Recruiting |
NCT04931329 -
Onco-haematology Vigilance Card
|
||
Terminated |
NCT02138812 -
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Recruiting |
NCT05356182 -
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
|
N/A | |
Terminated |
NCT02368951 -
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
|
Phase 1 | |
Not yet recruiting |
NCT05423808 -
Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.
|
N/A | |
Terminated |
NCT02439346 -
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
|
Phase 1 | |
Recruiting |
NCT05385718 -
Ezra Faster Scan Study
|
||
Completed |
NCT02457351 -
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
|
Phase 1 | |
Completed |
NCT02906423 -
Results From a Health System-wide Implementation of a Quality of Life Questionnaire
|
N/A | |
Completed |
NCT01409135 -
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
|
Phase 1 | |
Not yet recruiting |
NCT02327806 -
The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance
|
N/A | |
Completed |
NCT02639091 -
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT02366949 -
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Not yet recruiting |
NCT06097533 -
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02427490 -
A Problem-Solving Intervention for Family Caregivers in Palliative Oncology
|
N/A | |
Recruiting |
NCT05359848 -
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
|
N/A |